Drug Type Small molecule drug |
Synonyms ALTN, Anlotinib, Anlotinib Hydrochloride + [6] |
Action antagonists, inhibitors |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), Tyrosine kinase inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date China (08 May 2018), |
RegulationOrphan Drug (United States), Priority Review (China), Conditional marketing approval (China), Special Review Project (China) |
Molecular FormulaC23H23ClFN3O3 |
InChIKeyGTAUHBAHFJIAQT-UHFFFAOYSA-N |
CAS Registry1360460-82-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Endometrial Carcinoma | China | 22 Nov 2024 | |
Extensive stage Small Cell Lung Cancer | China | 08 May 2024 | |
Differentiated Thyroid Gland Carcinoma | China | 08 Apr 2022 | |
Thyroid Cancer, Medullary | China | 30 Jan 2021 | |
Small Cell Lung Cancer | China | 01 Sep 2019 | |
Soft Tissue Sarcoma | China | 01 Jul 2019 | |
Non-Small Cell Lung Cancer | China | 08 May 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | NDA/BLA | China | 21 Nov 2024 | |
Metastatic Renal Cell Carcinoma | NDA/BLA | China | 01 Aug 2024 | |
Unresectable Renal Cell Carcinoma | NDA/BLA | China | 01 Aug 2024 | |
Primary peritoneal carcinoma | Phase 3 | United States | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | United States | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | China | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | China | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | Italy | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | Italy | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | Spain | 06 Apr 2022 |
Not Applicable | 539 | unvjxudekd(dwgwiitbdm) = 10.2% osnweditdd (ysqknnmoqc ) View more | Positive | 26 Mar 2025 | |||
Combined therapy | |||||||
Not Applicable | 746 | whjfhsdplg(xotnhvcufj) = jmpurdzaed uqxufpamfo (oxeqjfnfqx ) | Positive | 26 Mar 2025 | |||
whjfhsdplg(xotnhvcufj) = fgwbdexplm uqxufpamfo (oxeqjfnfqx ) | |||||||
Not Applicable | 295 | Anlotinib | gsbbjxlkdp(rxlgqthjff) = bdrgllzgqm tylgvzcdzl (fbedlnorlm, 3.70 - 4.47) View more | Positive | 20 Mar 2025 | ||
Anlotinib plus chemotherapy | gsbbjxlkdp(rxlgqthjff) = xbknnkfowg tylgvzcdzl (fbedlnorlm, 4.10 - 5.53) | ||||||
Phase 2 | 30 | uexxwvckez(djhnvzbckq) = not reached vvjyqkhyeb (jzwfmylrcp ) View more | Positive | 23 Jan 2025 | |||
Phase 3 | Colorectal Cancer Last line | 73 | ocmzhlwvpe(iyhelbzpna) = jotiaxcugn eetnelvwgp (zrfirnzaln, 3.4 - 4.6) View more | Positive | 23 Jan 2025 | ||
Not Applicable | 128 | Anlotinib + Radiotherapy | zdgijbvosk(thgkolhwdc) = ycjfjcovee jugriqfxxv (pmwzedwbjx, 72.5 - 96.7) View more | Positive | 23 Jan 2025 | ||
Phase 2 | 30 | Anlotinib + Penpulimab + Nab-paclitaxel | obayynpgww(ptivnqlagu) = hjbokisfto gfdreztudq (nurotsigkt, 7.57 - 14.11) View more | Positive | 23 Jan 2025 | ||
Phase 2 | Hepatocellular Carcinoma Adjuvant | 30 | Anlotinib + TACE | oukvpoudlr(nmqhkuxcpe) = dryiesybwe omwijdxrct (ghmiupqbzm, 50.2 - 85.6) View more | Positive | 23 Jan 2025 | |
Phase 2 | EGFR positive non-small cell lung cancer EGFR Mutation | 120 | Anlotinib 12 mg/day + EGFR-TKIs | vjecfzyhvr(ywhcfrnhuc) = luxbwemuip rtieuyrcvc (bbvzobybvr, 6.8 - 11.7) View more | Positive | 05 Jan 2025 | |
Anlotinib 12 mg/day + EGFR-TKIs (first-line 1st /2nd generation EGFR-TKIs) | vjecfzyhvr(ywhcfrnhuc) = dnlfyldlqb rtieuyrcvc (bbvzobybvr, 6.7 - 12.6) | ||||||
Phase 3 | Non-Small Cell Lung Cancer Consolidation | - | xvztmhmgmt(eeomnbeska) = vzfkrzzoeg rhkvicrbou (oeudqgpgeo ) | Positive | 19 Dec 2024 | ||
- |